These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 28237206)
1. Toward a Hedonic Value Framework in Health Care. Basu A; Sullivan SD Value Health; 2017 Feb; 20(2):261-265. PubMed ID: 28237206 [TBL] [Abstract][Full Text] [Related]
2. The Questionable Economic Case for Value-Based Drug Pricing in Market Health Systems. Pauly MV Value Health; 2017 Feb; 20(2):278-282. PubMed ID: 28237209 [TBL] [Abstract][Full Text] [Related]
3. Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions. Sculpher M; Claxton K; Pearson SD Value Health; 2017 Feb; 20(2):234-239. PubMed ID: 28237201 [TBL] [Abstract][Full Text] [Related]
4. Evolving reimbursement and pricing policies for devices in Europe and the United States should encourage greater value. Sorenson C; Drummond M; Burns LR Health Aff (Millwood); 2013 Apr; 32(4):788-96. PubMed ID: 23569060 [TBL] [Abstract][Full Text] [Related]
5. The changing role of economic evaluation in valuing medical technologies. Rotter JS; Foerster D; Bridges JF Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):711-23. PubMed ID: 23252354 [TBL] [Abstract][Full Text] [Related]
6. Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6]. Willke RJ; Neumann PJ; Garrison LP; Ramsey SD Value Health; 2018 Feb; 21(2):155-160. PubMed ID: 29477393 [TBL] [Abstract][Full Text] [Related]
7. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options. Mühlbacher AC; Sadler A Value Health; 2017 Feb; 20(2):266-272. PubMed ID: 28237207 [TBL] [Abstract][Full Text] [Related]
8. Value-based differential pricing: efficient prices for drugs in a global context. Danzon P; Towse A; Mestre-Ferrandiz J Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269 [TBL] [Abstract][Full Text] [Related]
9. Switching costs in competitive health insurance markets: The role of insurers' pricing strategies. Lamiraud K; Stadelmann P Health Econ; 2020 Sep; 29(9):992-1012. PubMed ID: 32542729 [TBL] [Abstract][Full Text] [Related]
10. Early assessment of medical technologies to inform product development and market access: a review of methods and applications. Ijzerman MJ; Steuten LM Appl Health Econ Health Policy; 2011 Sep; 9(5):331-47. PubMed ID: 21875163 [TBL] [Abstract][Full Text] [Related]
11. An Evidence Framework for Off-Patent Pharmaceutical Review for Health Technology Assessment in Emerging Markets. Brixner D; Kaló Z; Maniadakis N; Kim K; Wijaya K Value Health Reg Issues; 2018 Sep; 16():9-13. PubMed ID: 29605800 [TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness and Dynamic Efficiency: Does the Solution Lie Within? Refoios Camejo R; Miraldo M; Rutten F Value Health; 2017 Feb; 20(2):240-243. PubMed ID: 28237202 [TBL] [Abstract][Full Text] [Related]
14. An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2]. Garrison LP; Pauly MV; Willke RJ; Neumann PJ Value Health; 2018 Feb; 21(2):124-130. PubMed ID: 29477389 [TBL] [Abstract][Full Text] [Related]
15. Addressing Pricing Power in Integrated Delivery: The Limits of Antitrust. Berenson R J Health Polit Policy Law; 2015 Aug; 40(4):711-44. PubMed ID: 26124302 [TBL] [Abstract][Full Text] [Related]
16. Early decision-analytic modeling - a case study on vascular closure devices. Brandes A; Sinner MF; Kääb S; Rogowski WH BMC Health Serv Res; 2015 Oct; 15():486. PubMed ID: 26507131 [TBL] [Abstract][Full Text] [Related]
17. Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian Approaches. Hagiwara Y; Shiroiwa T Med Decis Making; 2022 Jul; 42(5):672-683. PubMed ID: 35172648 [TBL] [Abstract][Full Text] [Related]
19. The application of economics concepts to stratified medicine--use of health economics data to support market access for stratified medicine interventions. Fugel HJ; Nuijten M; Faulkner E J Med Econ; 2014 May; 17(5):305-11. PubMed ID: 24654841 [TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness Analysis of Branded Drugs With Market Demand and Insurance. Pauly MV; Comanor WS; Frech HE; Martinez JR Value Health; 2021 Oct; 24(10):1476-1483. PubMed ID: 34593171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]